Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Afreen Shariff"'
Autor:
Laura C Cappelli, Bernice Kwong, Jarushka Naidoo, Jonathan Leventhal, Mario E Lacouture, Meghan J Mooradian, Douglas B Johnson, Justine Cohen, Aparna Hegde, Steven T Chen, Riley Fadden, Leyre Zubiri, Shawn Kwatra, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Yevgeniy R Semenov, Nicole R LeBoeuf, Krista M Rubin, Anna K Dewan, Alina Markova, Allireza Alloo, Daniel Q Bach, Amina Bougrine, Leeann Burton, Mariana Castells, Lauren Guggina, Victor Huang, Benjamin Kaffenberger, Daniela Kroshinsky, Cecilia Larocca, Jon McDunn, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Maxwell Sauder, Sheila Shaigany, Afreen Shariff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest,
Externí odkaz:
https://doaj.org/article/0f9ad47d419c4ad4b3131ec90c49be9f
Autor:
Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100337- (2022)
Introduction: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. Methods: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatmen
Externí odkaz:
https://doaj.org/article/4e8e10cbb46b4c6b9961babf7e012e44
Publikováno v:
AACE Clinical Case Reports, Vol 5, Iss 2, Pp e108-e111 (2019)
ABSTRACT: Objective: To describe a rare case of Wernicke encephalopathy (WE) as a result of hyperemesis gravidarum due to primary hyperparathyroidism (PHPT) in pregnancy.Methods: We present the clinical presentation, supportive laboratory values, dia
Externí odkaz:
https://doaj.org/article/b1679e9dd62645c188d3240bde9f6a54
Autor:
Tejas Desai, Vibhu Dhingra, Afreen Shariff, Aabid Shariff, Edgar Lerma, Parteek Singla, Swapnil Kachare, Zoheb Syed, Deeba Minhas, Ryan Madanick, Xiangming Fang
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0162376 (2016)
INTRODUCTION:Twitter channels are increasingly popular at medical conferences. Many groups, including healthcare providers and third party entities (e.g., pharmaceutical or medical device companies) use these channels to communicate with one another.
Externí odkaz:
https://doaj.org/article/32c4c582d34741518051e718322c0805
Is content really king? An objective analysis of the public's response to medical videos on YouTube.
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82469 (2013)
Medical educators and patients are turning to YouTube to teach and learn about medical conditions. These videos are from authors whose credibility cannot be verified & are not peer reviewed. As a result, studies that have analyzed the educational con
Externí odkaz:
https://doaj.org/article/c04a7f52f3aa40daa56999982f919ba5
Autor:
Tejas Desai, Afreen Shariff, Aabid Shariff, Mark Kats, Xiangming Fang, Cynthia Christiano, Maria Ferris
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e40253 (2012)
In recent years, the American Society of Nephrology (ASN) has increased its efforts to use its annual conference to inform and educate the public about kidney disease. Social media, including Twitter, has been one method used by the Society to accomp
Externí odkaz:
https://doaj.org/article/480c1e941cbc4240bbdccdea01e9f099
Publikováno v:
Journal of Palliative Medicine. 25:1715-1720
Immune checkpoint inhibitors (ICI), such as PD-1/PDL-1 and CTLA-4, have become widely used in the treatment of solid and hematological malignancies; their use and side effects are increasingly seen in the palliative care (PC) population. These drugs
Publikováno v:
Clinical Endocrinology.
Publikováno v:
Journal of the Endocrine Society. 7
Immune checkpoint inhibitors (ICIs) are a rapidly expanding class of targeted therapies effective in the treatment of various cancers. However, while efficacious, ICIs have been associated with treatment complications, namely immune-related adverse e
Autor:
Saadia A. Faiz, Lara Bashoura, Nicole R. LeBoeuf, Carey K. Anders, Afreen Shariff, Alexandra Thomas
Publikováno v:
American Society of Clinical Oncology Educational Book. :55-70
Agents with mechanisms novel to breast cancer care have been approved to treat breast cancer. These agents include drugs that target cyclin-dependent kinases, phosphoinositide 3-kinase PI3KCA gene mutations, PARP, checkpoint regulation, and novel ant